A new class of small molecule drugs, now in phase I clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and spread of glioblastoma.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
